Azvudine

Generic Name: Azvudine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁FN_₆O_₄

CAS Number: 1011529-10-4

Unique Ingredient Identifier: IJ2XP0ID0K

Background: Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

Indication: ⑴用于与核苷逆转录酶抑制剂及非核苷逆转录酶抑制剂联用，治疗高病毒载量的成年HIV-1感染患者。

⑵用于治疗普通型新型冠状病毒肺炎（COVID-19）成年患者。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Completed

Conditions: COVID-19
Azvudine

Interventions: Drug: Azvudine
Drug: Paxlovid

First Posted Date: 2024-04-05

Last Posted Date: 2024-04-05

Lead Sponsor: The First Affiliated Hospital of Zhengzhou University

Target Recruit Count: 32864

Registration Number: NCT06349655

Locations: 🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospective Cohort Study

Active, not recruiting

Conditions: COVID-19

Interventions: Drug: Azvudine

First Posted Date: 2023-08-23

Last Posted Date: 2023-09-21

Lead Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 4201

Registration Number: NCT06006611

Locations: 🇨🇳
The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection

Phase 4

Recruiting

Conditions: COVID-19

Interventions: Drug: Azvudine
Drug: Nirmatrelvir-Ritonavir

First Posted Date: 2023-01-25

Last Posted Date: 2023-02-27

Lead Sponsor: Shandong Provincial Hospital

Target Recruit Count: 410

Registration Number: NCT05697055

Locations: 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China

Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 at Increased Risk of Progressing to Severe Illness

Phase 2

Recruiting

Conditions: COVID-19 Respiratory Infection

Interventions: Drug: Placebo
Drug: Azvudine

First Posted Date: 2023-01-18

Last Posted Date: 2024-11-25

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 1096

Registration Number: NCT05689034

Locations: 🇨🇳
Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, Beijing, China

Evaluate Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19 in China

Phase 2

Recruiting

Conditions: COVID-19

Interventions: Drug: Azvudine
Drug: Placebo

First Posted Date: 2023-01-12

Last Posted Date: 2023-01-31

Lead Sponsor: Shanghai Henlius Biotech

Target Recruit Count: 300

Registration Number: NCT05682599

Locations: 🇨🇳
Huashan Hospital, Shanghai, Shanghai, China

Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients

Not yet recruiting

Conditions: COVID-19

First Posted Date: 2023-01-09

Last Posted Date: 2023-01-13

Lead Sponsor: Shanghai Henlius Biotech

Target Recruit Count: 400

Registration Number: NCT05675748

The Efficacy of Azvudine and Paxlovid in High-risk Patients With COVID-19: A Prospective Randomized Controlled Trial

Not Applicable

Recruiting

Conditions: SARS-CoV-2 Infection

Interventions: Drug: Paxlovid group
Drug: Azvudine

First Posted Date: 2022-12-08

Last Posted Date: 2022-12-08

Lead Sponsor: Southeast University, China

Target Recruit Count: 540

Registration Number: NCT05642910

Locations: 🇨🇳
Hohhot First Hospital, Hohhot, Inner Mongolia, China

Evaluate the Efficacy and Safety of Azvudine in Preventing SARS-Cov-2 Infection in Household Contacts of Covid-19

Phase 2

Recruiting

Conditions: SARS-CoV-2 Infection

Interventions: Drug: Azvudine
Drug: Placebo

First Posted Date: 2022-12-01

Last Posted Date: 2023-01-09

Lead Sponsor: Shanghai Henlius Biotech

Target Recruit Count: 1550

Registration Number: NCT05633433

Locations: 🇵🇭
Cebu Doctors' University Hospitol, Cebu City, Philippines
🇵🇭
University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Philippines
🇲🇾
International Islamic University Malaysia, Kuantan, Malaysia

and more 7 locations

An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia

Recruiting

Conditions: COVID-19 Respiratory Infection

Interventions: Drug: Azvudine

First Posted Date: 2022-11-18

Last Posted Date: 2023-10-03

Lead Sponsor: Qianfoshan Hospital

Target Recruit Count: 500

Registration Number: NCT05621993

Locations: 🇨🇳
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong, China

Study on Safety and Clinical Efficacy of AZVUDINE in Initial Stage COVID-19 Patients (SARS-CoV-2 Infected)

Phase 3

Completed

Conditions: COVID-19

Interventions: Drug: AZVUDINE placebo
Drug: AZVUDINE

First Posted Date: 2021-09-02

Last Posted Date: 2022-08-12

Lead Sponsor: HRH Pharmaceuticals Limited

Target Recruit Count: 312

Registration Number: NCT05033145

Locations: 🇧🇷
Clinical Research Unit / High Complexity Center (CRU/HCC) / Galzu Institute, Campos Dos Goytacazes, Rio De Janeiro, Brazil
🇧🇷
Hospital Moacyr Gomes de Azevedo, Cambuci, RJ, Brazil
🇧🇷
Hospital Santa Casa de Misericórdia de Campos, Campos Dos Goytacazes, RJ, Brazil

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy